Tumor-associated antigen-encoded epitope

A tumor-associated antigen-encoded epitope is a short peptide segment, usually 8–20 amino acids long, derived from a protein (antigen) that is overexpressed or aberrantly expressed in tumor cells relative to normal cells. These epitopes are presented on the tumor cell surface via major histocompatibility complex (MHC) molecules, where they can be recognized by antibodies (B cell epitopes) or T cell receptors (T cell epitopes). They are critical targets in cancer immunotherapies including monoclonal antibodies, cancer vaccines, and adoptive T cell therapies. Notable tumor-associated antigens providing clinically relevant epitopes include MAGE, NY-ESO-1, CEA, HER2/neu, and PSA. Some challenges associated with targeting these molecules include heterogeneous antigen expression and potentially harmful autoimmunity if the antigen is not fully tumor-specific[2][3][4].

Other names

Tumor-associated epitopeTAA-encoded epitopeCancer antigen epitope

Antibody binding T cell-mediated cytotoxicity Immune checkpoint modulation Vaccine-induced immunity